Results 101 to 110 of about 44,418 (298)

Sulfonylureas

, 2022
Antonio Pulgar
openalex   +1 more source

Sodium‐glucose co‐transporter 2 inhibitors and obesity‐associated cancers in people with type 2 diabetes: A real‐world observational study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To investigate the association between sodium‐glucose co‐transporter 2 inhibitors (SGLT‐2i) and obesity‐associated cancers (OAC) in individuals with type 2 diabetes (T2D). Materials and Methods This retrospective cohort study used data from the TriNetX US Collaborative Network.
Testimony Ipaye, Jonathan Goldney, Thomas Yates, Francesco Zaccardi, Kamlesh Khunti, Elina Akalestou, Melanie J. Davies, Karen Brown, Dimitris Papamargaritis   +8 more
wiley   +1 more source

Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Background Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) improve glycemic outcomes in people with type 2 diabetes, but their generalizability to routine clinical practice remains uncertain. Aim To evaluate the real‐world effectiveness of sustained GLP‐1 RA use on haemoglobin A1c (HbA1c) over 1 to 4.5 years, using dipeptidyl peptidase 4
Kathrine Kold Sørensen, Puriya Daniel Würtz Yazdanfard, Bochra Zareini, Hannah Karin Wood‐Kurland, Ulrik Pedersen‐Bjergaard, Mikkel Porsborg Andersen, Jens Michelsen, Henrik Imberg, Marcus Lind, Sara Hallström, Stefanie Lanzinger, Anders Munch, Johan Sebastian Ohlendorff, Thomas Alexander Gerds, Christian Torp‐Pedersen, The REDDIE Consortium   +15 more
wiley   +1 more source

Impact of early and tight HbA1c control on the risk of long‐term complications and cardiovascular death in patients with type 2 diabetes from the Swedish National Diabetes Register

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the relationship between haemoglobin A1c (HbA1c) levels and incidence of long‐term complications in patients with type 2 diabetes (T2D). Materials and Methods This long‐term, retrospective study acquired patient data from the Swedish National Diabetes Registry and linked national registers between 1 January 1998 and 31 December ...
Julie Mount, Kristina Boye, Jeremie Lebrec, Emily Wilkes, Kari Ranta, Anders Toll, Erik Joas, Irina Sveide, Björn Eliasson, Josefine Redig   +9 more
wiley   +1 more source

K-ATP channel gene expression is induced by urocortin and mediates its cardioprotective effect [PDF]

, 2002
Background-Urocortin is a novel cardioprotective agent that can protect cardiac myocytes from the damaging effects of ischemia/reperfusion both in culture and in the intact heart and is effective when given at reperfusion.Methods and Results-We have ...
Chanalaris, A, Comini, L, Ferrari, R, Hubank, M, Knight, RA, Latchman, DS, Lawrence, KM, Pasini, E, Scarabelli, T, Stephanou, A, Tinker, A, Townsend, PA   +11 more
core  

The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]

, 2013
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core   +2 more sources

Characterisation of steady‐state pharmacokinetics and glucodynamics of once‐weekly insulin efsitora alfa in individuals with type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the steady‐state pharmacokinetics (PK) and glucodynamic effects of insulin efsitora alfa (efsitora) over a weekly interval in adults with type 2 diabetes (T2D). Materials and Methods This open‐label, multiple dose, euglycaemic clamp study was conducted in 56 insulin naïve adults with T2D (mean [±SD] age, 61.9 ± 5.98 years ...
Jennifer Leohr, Oliver Klein, Tim Heise, Eric Zijlstra, Juliana M. Bue‐Valleskey, Subha Suriyapperuma, Ryan Jarrett, Douglas James, Micheal Case, David Waters, Edward Pratt, Helle Linnebjerg   +11 more
wiley   +1 more source

Sulfonylureas.

JPMA. The Journal of the Pakistan Medical Association, 2015
This review describes the basic and clinical pharmacology of sulfonylureas. It undertakes a balanced assessment of the advantages and limitations of sulfonylureas, and compares the use of various sulfonylureas in different clinical situations. The authors suggest pragmatic guidance to facilitate safe and effective use of this class of drugs, and thus ...
Sanjay, Kalra, Yashdeep, Gupta
openaire   +1 more source

Impact of specialised endocrinology care on metabolic control and healthcare utilisation outcomes after kidney transplantation in patients with diabetes: A 12‐month observational cohort study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate whether an endocrinology‐integrated transplant clinic and differing healthcare delivery models are associated with metabolic outcomes during the first year after kidney transplantation in recipients with pre‐existing diabetes.
Joaquin Lado‐Abeal, Francisco Gude, Maria Jose Ginzo‐Villamayor, Khalid Al‐Zubaidi, Jacqueline C. Stocking, Gemma Rodriguez‐Carnero, Aili Guo, Prasanth Surampudi, Caroline Lenaerts, Vedesh K. Babu, Deborah Plante, Yihung Huang, Antia Fernandez‐Pombo   +12 more
wiley   +1 more source

Photo-Switchable Sulfonylureas Binding to ATP-Sensitive Potassium Channel Reveal the Mechanism of Light-Controlled Insulin Release

, 2021
Katarzyna Walczewska-Szewc, Wiesław Nowak   +1 more
openalex   +1 more source